% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lazzeroni:307500,
author = {M. Lazzeroni and A. Ureba and H. Schäfer$^*$ and N.
Nicolay$^*$ and A. Rühle$^*$ and D. Baltas$^*$ and A. Dasu
and P. T. Meyer and M. Mix and I. Toma-Dasu and A. L.
Grosu$^*$},
title = {{B}iologically {I}ndividualized {R}adiotherapy {B}ased on
{PET}: {A} {N}ovel {A}pproach to {T}reatment {O}ptimization
of {H}ead and {N}eck {C}ancer.},
journal = {Journal of nuclear medicine},
volume = {nn},
issn = {0097-9058},
address = {New York, NY},
publisher = {Soc.},
reportid = {DKFZ-2026-00005},
pages = {nn},
year = {2025},
note = {epub},
abstract = {Current radiotherapy for malignant tumors often adopts a
'one-size-fits-all' approach, prescribing the same
irradiation dose for patients with similar clinical
indications. However, advancements in functional imaging
allow for biologically individualized strategies, with dose
distribution tailored to the specific tumor biology. This
study proposes a novel approach to biologically
individualized radiotherapy, exploiting the synergistic
combination of the tumor clonogenic cell information from
[18F]FDG PET images and radiosensitivity from
[18F]fluoromisonidazole (FMISO) PET images. Methods:
Twenty-eight patients with head and neck squamous cell
carcinoma (HNSCC) were analyzed. Using imaging biomarkers,
individualized tumor profiles were obtained from oxygen
partial pressure and clonogenic cell density maps derived
from [18F]FMISO and [18F]FDG PET, respectively.
Dose-escalated radiotherapy plans aiming at $95\%$ tumor
control probability (TCP) were generated using automated
planning. Plans were assessed for clinical feasibility and
expected TCP. Results: Planned dose distributions achieved
greater than $90\%$ TCP in all cases. All treatment plans
met standard clinical feasibility criteria for the main
organs-at-risk constraints, except for the few cases with
significant target overlap, demonstrating the overall
feasibility of the personalized strategy. Conclusion: The
proposed biologically individualized treatment strategy
demonstrated feasibility and clinical applicability.
Combining [18F]FDG and [18F]FMISO PET imaging potentially
shifts the success rate of HNSCC treatment from
approximately $60\%$ at 5 y, as reported in the literature,
to a projected TCP of $90\%.$ This treatment strategy holds
promise for improving patient outcomes through more precise
and effective treatment.},
keywords = {biologically individualized radiotherapy (Other) /
clonogenic cell density (Other) / dual-tracer PET (Other) /
head and neck squamous cell carcinoma (Other) / tumor
hypoxia (Other)},
cin = {FR01},
ddc = {610},
cid = {I:(DE-He78)FR01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41469160},
doi = {10.2967/jnumed.125.270403},
url = {https://inrepo02.dkfz.de/record/307500},
}